BG
LSTA icon

BlackRock Group’s Lisata Therapeutics LSTA Stock Holding History

BlackRock Group’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-41
Closed -$43K – 2844
2014
Q1 		$43K Buy
+41
New +$44.5K ﹤0.01% 2662

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

BlackRock Group's LSTA Position: Q2 2014 in Review

BlackRock Group sold out of Lisata Therapeutics (LSTA) in Q2 2014, closing a stake of 41 shares — an estimated $43K sold.

BlackRock Group first reported a position in LSTA in Q1 2014 and held it in 1 quarter. The position peaked at $43K in Q1 2014. 58 funds tracked by Wall St. Rank hold LSTA as of Q2 2014.

  • BlackRock Group reported no remaining Lisata Therapeutics position as of Q2 2014 after selling out during the quarter.
  • BlackRock Group sold 41 Lisata Therapeutics shares in Q2 2014, an estimated $43K.
  • BlackRock Group first reported a position in Lisata Therapeutics in Q1 2014 and held it in 1 quarter.
  • BlackRock Group's Lisata Therapeutics position peaked at $43K in Q1 2014.
  • 58 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2014.

Based on BlackRock Group's 13F filing for Q2 2014, filed 6 Aug 2014.